<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30089478</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2407</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>BMC cancer</Title>                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study.</ArticleTitle>            <Pagination>                <MedlinePgn>800</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4700-3</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this retrospective study, data from patients listed in the Korea Central Cancer Registry during 1993-2014 were analysed, to investigate the incidence and survival of second primary cancers (SPCs) after a diagnosis of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancer.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The standardised incidence ratio (SIR) and survival outcomes of patients with SPCs among POFT cancer survivors were analysed.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 20,738 POFT cancer survivors, 798 (3.84%) developed SPCs, at an average interval of 5.50 years. SPC risk in POFT survivors (SIR, 1.29) was higher compared to the general population. The most high-risk type of SPC was leukaemia (3.07) followed by the lung and bronchus (1.80), colon (1.58), rectum and rectosigmoid junction (1.42), thyroid (1.34), and breast (1.26). In women aged &lt; 60 years, cancer of the breast (1.30), ascending colon (2.26), and transverse colon (4.07) as SPCs increased. Up to 10 years after POFT cancer treatment, leukaemia risk increased, especially in those &lt; 60 years, with serous histology, and with distant stage, which required aggressive chemotherapy. The median overall survival time was 12.8 years and 14.3 years in women with POFT cancer and SPCs, respectively. Thyroid and breast cancers were favourable prognostic markers among SPCs.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The overall SPC risk increases in POFT cancer survivors, especially in those &lt; 60 years. The cancer risk of breast and the proximal colon increase based on hereditary predisposition, while leukaemia likely develops from aggressive treatment. The median overall survival is favourable in POFT cancer survivors with SPCs.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lim</LastName>                    <ForeName>Myong Cheol</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Gynecologic Oncology, Obstetrics and Gynecology, Irvine Medical Center, University of California, California, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Uterine Cancer and Center for Clinical Trials, Hospital, National Cancer Center, Goyang, Republic of Korea.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cancer Healthcare Research Branch, Research Institute, National Cancer Center, Goyang, Republic of Korea.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Cancer Control &amp; Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Won</LastName>                    <ForeName>Young-Joo</ForeName>                    <Initials>YJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cancer Control &amp; Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea. astra67@ncc.re.kr.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cancer Registration and Statistics Branch, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea. astra67@ncc.re.kr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lim</LastName>                    <ForeName>Jiwon</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Registration and Statistics Branch, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Salehi</LastName>                    <ForeName>Tahereh</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Gynecologic Oncology, Obstetrics and Gynecology, Irvine Medical Center, University of California, California, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yoo</LastName>                    <ForeName>Chong Woo</ForeName>                    <Initials>CW</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Uterine Cancer and Center for Clinical Trials, Hospital, National Cancer Center, Goyang, Republic of Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bristow</LastName>                    <ForeName>Robert E</ForeName>                    <Initials>RE</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Gynecologic Oncology, Obstetrics and Gynecology, Irvine Medical Center, University of California, California, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>NCC-1610200</GrantID>                    <Agency>National Cancer Center</Agency>                    <Country>Republic of Korea</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Cancer</MedlineTA>            <NlmUniqueID>100967800</NlmUniqueID>            <ISSNLinking>1471-2407</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2011 Dec;123(3):456-60</RefSource>                <PMID Version="1">21855120</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Jpn J Clin Oncol. 2010 Dec;40(12):1121-7</RefSource>                <PMID Version="1">20965939</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Clin Oncol. 2009 Nov;135(11):1593-9</RefSource>                <PMID Version="1">19499246</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2017 Jan;67(1):7-30</RefSource>                <PMID Version="1">28055103</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Obstet Gynecol. 2012 Aug;120(2 Pt 1):235-40</RefSource>                <PMID Version="1">22776961</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44</RefSource>                <PMID Version="1">18656380</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res Treat. 2017 Apr;49(2):306-312</RefSource>                <PMID Version="1">28301926</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gynecol Oncol. 2017 Jul;28(4):e51</RefSource>                <PMID Version="1">28541638</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gynecol Oncol. 2013 Oct;24(4):298-302</RefSource>                <PMID Version="1">24167664</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2016 Jan;23(1):186-95</RefSource>                <PMID Version="1">25986870</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2012 Jan 25;307(4):382-90</RefSource>                <PMID Version="1">22274685</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Medicine (Baltimore). 2015 Sep;94(38):e1626</RefSource>                <PMID Version="1">26402833</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Jun 25;372(26):2509-20</RefSource>                <PMID Version="1">26028255</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S111-22</RefSource>                <PMID Version="1">26433667</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2015 Apr 7;313(13):1347-61</RefSource>                <PMID Version="1">25849179</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Fallopian tubal cancer</Keyword>            <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>            <Keyword MajorTopicYN="N">Primary peritoneal cancer</Keyword>            <Keyword MajorTopicYN="N">Second primary</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30089478</ArticleId>            <ArticleId IdType="doi">10.1186/s12885-018-4700-3</ArticleId>            <ArticleId IdType="pii">10.1186/s12885-018-4700-3</ArticleId>            <ArticleId IdType="pmc">PMC6083613</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>